Table 3.
Clinical information of IBD patients with active disease, clinical remission and steroid-free clinical remission.
| Characteristics | IBD patients (n = 209) | ||
|---|---|---|---|
| Active disease (n = 101) | Clinical remission (n = 108) | Steroid-free clinical remission (n = 78) | |
| Male (%) | 53 (52.5%) | 50 (46.3%) | 37 (47.4%) |
| Age (mean ± SD, years) | 45.2 ± 15.2 | 49.2 ± 16.1 | 50.1 ± 16.3 |
| Current smoking (n, %) | 0 (0%) | 6 (2.8%) | 5 (6.4%) |
| Current NSAID use (n, %) | 1 (0.5%) | 2 (1%) | 2 (2.6%) |
| Married (n, %) | 55 (54.5%) | 70 (64.8%) | 27 (34.6%) |
| Postgraduate Certificate Diploma (n, %) | 68 (67.3%) | 77 (71.3%) | 55 (70.5%) |
| Ulcerative colitis | 50 (49.5%) | 56 (51.9%) | 43 (55.1%) |
| E1: proctitis | 8 (16%) | 5 (8.9%) | 5(11.6%) |
| E2: left-sided colitis | 18 (36%) | 24 (42.9%) | 17 (39.5%) |
| E3: extensive colitis | 24 (48%) | 27 (48.2%) | 20(46.5%) |
| Crohn’s disease | 51(50.5%) | 52 (48.1%) | 35 (44.8%) |
| Location | |||
| L1: ileum | 14 (27.5%) | 13 (25%) | 9(25.7%) |
| L2: colon | 9 (17.5%) | 12 (23.1%) | 10 (48.6%) |
| L3: ileocolon | 27 (53%) | 24 (46.2%) | 16 (45.7%) |
| L4: upper GI | 1 (2%) | 3 (5.7%) | 0 (0%) |
| Behavior | |||
| B1: inflammatory | 29 (56.9%) | 36 (69.2%) | 25(71.4%) |
| B2: stricturing | 9 (17.6%) | 4 (7.7%) | 1 (2.9%) |
| B3: penetrating | 13 (25.5%) | 12 (23.1%) | 9 (25.7%) |
| Perianal disease | 6 (5.9%) | 5 (4.6%) | 3 (3.8%) |
| Current IBD medication | |||
| Corticosteroids | 45 (44.6%) | 30 (27.8%) | 0 (0%) |
| 5-Aminosalicylate | 72 (71.3%) | 73 (67.6%) | 52 (66.7%) |
| Immunomodulators | 65 (64.3%) | 74 (68.5%) | 53 (67.9%) |
| Biologic agents | 13 (12.9%) | 11 (10.2%) | 7 (9%) |